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Abstract
Background: Spermatocytic seminoma (SS) is a distinct testicular germ cell tumor, representing less than 1% of
testicular cancers. The clinical features that distinguish ss from classical seminoma are an older age at presentation
and a reduced propensity to metastasize. The aim of our work is to underline the epidemiological, clinical,
histological, therapeutical and prognostic features of this tumor.
Findings: A retrospective analysis of patients referred to the national institute of oncology with seminoma,
identified from the institutional tumor registry, between January 1996 and February 2009, was performed.
Information reviewed included demographics, clinical, pathological staging, surgical management, adjuvant
treatment and last follow-up. We studied four cases of spermatocytic seminoma, which represented 1% of
testicular tumor and 6,4% of all seminoma treated at our institution during the study period. Median age at
diagnosis was 45 years (range: 42-48). Mean delay before consulting was 9 months and the mean tumor size was
13,75 cm (10-18 cm). No patient had a history of maldescended testis. The main clinical complaint was unilateral
testis mass with low progression. Pathology showed that tumors had a polymorphic appearance with small,
intermediate and large cells. In all cases, the tumor was limited to the testis. immunohistochemical studies showed
that tumors were negative for all the classical antibodies tested (LCA, cytokeratins, PLAP, lymphoid markers, CD117).
Thoraco-abdomino-pelvic CT scan and tumor markers (AFP and hCG) were normal. All patients were Stage I.
Treatment consisted on an orchidectomy associated with adjuvant radiotherapy in one patient. After a median
follow-up of 6 years ranging from 2 to 15 years, we did not note any relapse or metastasis.
Conclusion: The diagnosis of spermatocytic seminoma must be considered in all patients aged of more than 50
with testicular tumor. With only three cases of metastatic disease confirmed in the literature, this is a subgroup of
patients in whom radiotherapy can safely be omitted.
Introduction
Spermatocytic seminoma (SS) is an uncommon neo-
plasm first described by Masson in 1946 and rarely
occurs before the fifth decade. It represents 1 to 2% of
germ cell tumors and 4 to 7% of all seminoma patients
[1-3]. Unlike classical seminoma originated from undif-
ferentiated germ cells, spermatocytic seminoma may
derive from spermatogonia and represented a more dif-
ferentiated type of germ cell neoplasm. To date, more
than 200 cases have been reported, most of them with
benign behavior [1-5]. Because of its rarity, the diagnosis
of spermatocytic seminoma is difficult, posing the pro-
blem of differential diagnosis essentially with testicular
lymphoma and classical seminoma, especially after mid-
dle age. Immunohistochemical staining can be extremely
helpful to assess the diagnosis based on the negativity of
all tested classic markers [6,7]. Spermatocytic seminoma
rarely metastasizes and there is no documented benefit
of radiotherapy or preventive chemotherapy [8-10]. The
aim of our work is to underline the epidemiological,
clinical, histological, therapeutical and prognostic fea-
tures of these tumors through a retrospective study con-
ducted at the National Institute of Oncology which is
considered the largest institute on cancer treatment in
our country.
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Patients and Methods
Between 1996 and 2009, 396 patients with testicular
neoplasms of which 160 seminoma were seen. Review of
these cases revealed 4 cases of spermatocytic seminoma
with an incidence of 2.3%. All patients had undergone
orchidectomy at other hospitals and had been referred
for subsequent management. Data were collected from
patient medical files and the following parameters were
recorded: age, primary tumor size, presence of lympho-
vascular invasion in tumor, presence of rete testis inva-
sion, stage of disease at presentation, relapse and
survival. All histological diagnoses have been reviewed
at our institution where extensive immunochemistry
was performed. Characteristics of spermatocytic semi-
noma, were appreciated on closer inspection with a tri-
partite cell population composed of a small lymphocyte-
like, intermediate-sized and large cells Immunohisto-
chemically, markers including LCA, CD30, CD20,
vimentin, PLAP, AFP, EMA, cytokeratin AE1/AE3, and
CD117 were tested in the four cases Patients were
staged with thoraco-abdomino-pelvic CT scan, tumor
markers (alphafetoprotein AFP and beta-human chorio-
nic gonadotrophin hCG) and serum LDH. All patients
had were staged according to the American Joint Com-
mittee on Cancer (AJCC 2007/TNM staging system).
Three patients were managed with inguinal orchidect-
omy followed by surveillance. In one patient, a scrotal
orchydectomy was done initially for scrotal traumatism
in other establishment where a tumor was discovered
then referred to our institute. Diagnosis of spermatocy-
tic seminoma was done and a resection of the spermatic
cord was performed. This patient received prophylactic
radiotherapy.
Radiotherapy was delivered using megavoltage
photons, to a dose of 25 Gy in 20 fractions over 4
weeks, prescribed to mid-plane. The treatment volume
encompassed the para-aortic and ipsilateral pelvic lymph
nodes. A recommended schedule of surveillance for
stage I seminoma was adopted in our patients : 4-
monthly clinical examination, abdominopelvic CT scan,
tumour markers and chest X-ray for the first 3 years,
then every six months for year 4 to 7 and finally every
12 months Clinical and pathological information con-
cerning these four cases are summarized in (Table 1).
Consent and statement of ethical approval
As the treatment of each patient was decided by the
medical staff of the centre, oral consent was obtained
from the subjects and was approved by the institutional
review boards of the National Institute of Oncology,
Cancer Centre in Rabat. This study was approved by the
institutional review boards of National Institute of
Oncology, in Rabat
Results
We studied four cases of spermatocytic seminoma, that
represents 1% of testicular neoplasm and 2,5% of all
seminoma treated at our institution during the study
period. Median age at diagnosis was 45 years-old (42-
48). All the tumors had arisen in normally descended
testes. The main clinical complaint was unilateral non-
painful testis mass with low progression. The median
duration to consultation was 9 months (range: 3 months
to 5 years). The tumor was right-sided in 3 cases and
left-sided in one. Serum alphafetoprotein, hCG and
LDH were normal. Histologically, all tumors examined
showed features of spermatocytic seminoma. Tumors
had a polymorphic appearance with small, intermediate
and large cells. The stroma displayed variable microcyst
formation, without fibrosis or lymphocytic infiltration (
[Figure 1]. None was combined with other germ cell
tumors or associated with sarcomatous component. In
all cases, the tumor was limited to the testis ( Rete testis
and lymphovascular invasion was not observed). In the
peritumoral tissue, there was no intratubular germ cell
proliferation. Immunohistochemical studies showed that
tumors were negative for all the classical antibodies
tested (LCA, CD30, CD20, vimentin, PLAP, AFP, EMA,
CD117 and cytokeratin AE1/AE3))[Figure 2]. All
patients were Stage I (disease confined to the testis and
no evidence of metastasis on clinical staging). All
patients underwent orchidectomy and only one received
adjuvant radiotherapy. The others were placed on sur-
veillance program. After a median follow-up of 6 years
ranging from 2 to 15 years, we did not notice any
relapse or metastasis.
Discussion
Spermatocytic seminoma is a rare germ cell tumor, first
described by Masson in 1946[11]. It represents a distinct
testicular neoplasm with an independent pathogenic
pathway and low probability to metastasize. Prognosis is
more favorable than classic seminoma in the absence of
sarcomatous contingent or metastases. Although rare,
these tumors are more common than is suggested by the
approximately 200 cases that are currently documented
in the literature as case reports and case series. A litera-
ture review revealed that the incidence of spermatocytic
seminoma in different series varies between 1.7-12% of
all serminomas [12], but most of the larger series showed
a frequency of 1,1-7,4%[13-16]. For example among
9,658 cases of primary malignant testicular neoplasms
recorded in the Australian cancer registries over 20 years,
spermatocytic seminoma was identified in 58 cases, yield-
ing an incidence rate of less than 1,1% of all seminoma
[15]. Similarly, this uncommon tumor represents at our
institution 1,1% of all testicular germ cell tumors.
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Phenotypic characterization and origin cell of sperma-
tocytic seminoma (SS) are different from other subtypes
of Germ-cell tumours (GCTs). In fact, GCTs are a het-
erogeneous group of neoplasms characterized by their
chromosomal complement and developmental potential
[17 = nrc]. GCT characteristics can either be due to the
process of tumorigenesis or just a reflection of normal
embryonal development, which contributes to the com-
plexity of these tumours [17]. Based on epidemiology,
clinical presentation, phenotypic characterization, chro-
mosomal constitution and genomic imprinting, the
group of testicular GCTs comprises three of the five
GCT entities: the teratomas and yolk-sac tumours of
newborn and infants; the seminomatous and non-semi-
nomatous tumours of adolescents and young adults; and
the spermatocytic seminomas of the elderly [18,19].
Looijenga and al had presented data demonstrating that
spermatocytic seminomas, referred to as the type III
Table 1 Spermatocytic seminoma patient characteristics
Case
N°




Laterality therapy metastase Follow up
1 46 3 10 × 8 × 8 cm Left Orchidectomy and radiation
therapy.
None A & W 15 years
postop
2 42 12 12 cm Right Orchidectomy None A & W 8 years
postop
3 44 60 16,5 cm right Orchidectomy None A & W 3 years
postop
4 48 18 18 cm(whole testis
affected)
right Orchidectomy None A & W 2 years
postop
A & W = Alive and well with no evidence of disease.
a.
b.
Figure 1 Spermatocytic seminoma showing a characteristic mixture of small, medium-sized and large and multinucleated cells.(H &
Ex200), with round nuclei, and marked mitotic activity (H & E, ×1000).
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GCTs, have a distinct pathogenesis from seminomas and
non-seminomas, most likely originating from primary
spermatocytes. Genome-wide analyses of genomic
changes and expression profiling confirm the origin of
spermatocytic seminoma from primary spermatocytes
that have at least initiated prophase meiosis. Therefore,
the published results indicate that structural chromoso-
mal changes are rare, and that gain of chromosome 9 is
the only recurrent imbalance [20]. The paternal pattern
of genomic imprinting of spermatocytic seminoma is
consistent with this tumour arising from a germ cell
that is more mature than a Primordial germ cells [21].
Few spermatocytic seminomas have been studied at
the ultrastructural level. Morroni and al have described
the ultrastructural features of classical seminoma in
comparison with SS. This study indicate that detection
of intermitochondrial cement in spermatocytic semi-
noma confirms a more differentiated phenotype com-
pared with classical seminoma [22].
It is well known that SS is exclusively a testicular
tumor, which has never been observed in ovarian or
ectopic testis. SS is not associated with any known risk
factors for germ cell tumors like cryptorchidism, subfer-
tility or gonadal dysgenesis [13,23].
Clinically, the main difference between spermatocytic
and classical seminoma is the age of occurrence. Sper-
matocytic seminoma tends to occur more commonly,
in men aged over 50, while in classical seminoma, the
age at diagnosis is between 25 and 40 years. In our
series, patients were younger than reported in the lit-
erature all patients were aged less than 50. The dura-
tion of symptoms was on the whole longer compared
with classical seminoma, indicating a slower evolution
and less malignant biological behavior. Similarly, in
our series, patients’ history varied from 3 months to 5
years with an average of 14 months. The large size of
the spermatocytic as compared to the classical semi-
noma was noted by Masson[11]. The size of the tumor
was ranged from 10 to 16 cm with an average of 6.6
cm[14], usually replacing the whole testis. Similarly, in
the present cases, the mean tumor size was 13,5 cm.
The histological characteristics of all the tumors
Figure 2 Negativity of tumoral cells for PLAP antibody (×400).
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studied were basically similar and conformed to those
described by other investigators [9,14]. Spermatocytic
seminoma is morphologically characterized by the pre-
sence of small, intermediate and large cells with simila-
rities to spermatogonia and spermatocytes, [17] These
views received further support from others studies
reporting different histogenesis of SS in comparison
with CS and based on analysis of DNA ploidy and
immunohistochemical profiles. While SS contains
diploid to polyploidy cells as the principal finding, CS
is predominantly aneuploid [5]. Differential features
between Spermatocytic and Classical Seminoma are
presentend in table 2. Immuhistochemically, Placental
like alkaline phosphatase (PLAP)-negative cells are a
typical feature of SS, whereas CS cells stain positively
for PLAP [9,24]. However, focal PLAP positivity has
been observed [25]. In general, the SS cells show focal,
weak c-Kit positivity. Decaussin reports 7 cases of
spermatocytic seminoma in which c-Kit was expressed
in all cases[2]. This membranous positivity was focal in
4 cases, very strong, and diffuse in the 3 others. In
contrast, none of the 11 SS reported by Stoop
expressed c-kit [26]. Other markers such as cytokera-
tin, neuroendocrin, and lymphoid marquers are
reported to be negative [1,2,26]. Thus, c-kit appears as
the only immunohistochemical positive marker for this
tumor. This positivity does not provide a diagnostic
aid, first because it is inconstant depending on the
antibodies used, then because the classical seminoma,
main differential diagnosis, expresses constantly this
protein. Finally, in doubtful cases, including those with
differential diagnosis against lymphoma, immunohisto-
chemical analysis can be useful in achieving the correct
diagnosis. Similar findings were noted in our cases
with negativity of all markers tested.
Another important histological feature is the presence
of the anaplastic variant of spermatocytic seminoma.
Only three reports describing six cases of this variant
has been noted to date [1,27,28]. This rare variant is
characterized by constant features including extensive
necrosis, multiple mitotic figures, and vascular and tuni-
cal invasion. Despite these worrisome features, the pre-
sence of an anaplastic component does not seem to
impact the excellent prognosis of spermatocytic semi-
noma. The malignant potential of SS is very low. Only
proven three cases of metastatic spermatocytic semi-
noma have been described [29-31]. These three patients
did not receive adjuvant radiation therapy after orchiect-
omy. In one case, two cycles of carboplatin monother-
apy (400 mg/m2) were administered according to the
treatment regimen for classical seminoma at the institu-
tion [30]. Metastatic disease has been also reported
when spermatocytic seminoma is associated with sar-
coma. The sarcomatous component is usually rhabdo-
myosarcoma or undifferentiated, high-grade sarcoma
and it appears that the metastatic disease develops
usually from the sarcomatous elements [32] The sarco-
matous dedifferentiation in the spermatocytic seminoma
was associated in the most reported cases with aggres-
sive behavior and poor outcome [32,33].
When metastatic disease was confirmed, cisplatin-
based chemotherapy (PEB) was administered as in clas-
sical seminoma. This protocol was poorly effective in
reducing the retroperitoneal mass in one case [31].
Although metastatic spread is a rare event, observed
metastatic cases indicate the need for meticulous staging
and some kind of follow-up in patients with spermato-
cytic seminoma. Following orchiectomy for clinical stage
I testicular classical seminoma, active surveillance, adju-
vant limited field radiation therapy (RT), or a short
Table 2 Differential Features between Spermatocytic and Classical Seminoma
Classical seminoma SS
incidence 2% 40%
Usual age on presentation (yrs) 20-50 ≥ 50 ans
Occurrence in undescended testis
(%)
8-10% No documented case
Site Testis only Testis, ovary, mediastinurn, retroperitoneum and pineal region
Cell types one 3 types: small lymphocyte-like, intermediate-sized and large
cells
lymphocytic infiltration Rare ou absent Present, may be abundant
DNA ploidy Aneuploid Diploid, Hyperdiploid
intratubular component Typical IGCN(intratubular germ cell
neoplasia)
Infiltrating component spermatocytic seminoma
metastases Metastases common 3 cases
PLAP positive Negative
prognosis Stage depending Excellent. Better than classical seminoma
PLAP: immunohistochemistry for placental alkaline phosphatase;
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course (one or two cycles) of adjuvant single agent car-
boplatin all offer an extremely high likelihood of cure.
The choice of therapy for an individual patient requires
a consideration of the patient’s ability to comply with a
surveillance regimen as well as acute and delayed com-
plications of adjuvant chemotherapy or adjuvant RT.
We generally suggest active surveillance for patients
able to comply with an intensive follow-up schedule,
because of the decreased risk of late complications and
because of the ability to achieve the same overall cure
rate when patients who relapse are treated appropriately.
Primary tumor size greater than 4 cm and invasion of
the rete testis have been identified as independent fac-
tors associated with an increased risk of relapse in mul-
tivariate analysis [34]. However, surveillance is not
contraindicated in men with these features, provided the
patient understands that the risk of relapse may exceed
30 percent and that they must adhere rigorously to the
surveillance protocol. For patients with clinical stage I
seminoma for which active surveillance is not appropri-
ate and for those who want to minimize any risk of
relapse, adjuvant chemotherapy with single agent carbo-
platin is suggested rather than RT. In all cases, there is
no unanimity in the therapeutic procedure of SS. It was
stated that spermatocytic seminoma is a radiosensitive
tumor [35], but no direct evidence for this sensitivity
was presented and the usefulness of postoperative radio-
therapy was doubted. However, the majority of reported
patients in the literatture with SS have received post-
orchidectomy radiotherapy to the draining lymph node
area. Where the seven patients with spermatocytic semi-
noma managed with surveillance in The series of Chung
and al [14], Equal numbers of patients in the series of
Pendlebury and al underwent surveillance postorchidect-
omy as received radiotherapy [16]; In the two series,
there has been no relapse. SS rarely metastasizes and
there is no documented benefit of a preventive che-
motherapy. In our small series, although existence of
factor of poor prognosis (size > 4 cm), only the first
patient treated in 1996 received adjuvant radiotherapy
while the 3 others patients were managed by surveil-
lance. Whilst RT or surveillance are both valid methods
of management for stage I classic seminoma, active sur-
veillance in the specific subgroup of SS it is more appro-
priate. The main benefit of surveillance is that it avoids
unnecessary treatment and the associated treatment-
related adverse effects.
Conclusion
SS is a distinct neoplasm both clinically and pathologi-
cally from classical seminoma and it differs from the lat-
ter especially by its behavior, characterized by an almost
complete inability to metastasize with only very few
examples described with metastatic behavior. The fact
that radiotherapy is not necessary is important in view
of the fact that many patients with spermatocytic semi-
noma are elderly and may be adversely affected by
treatment.
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